This analysis reveals rising mortality trends in myelodysplastic syndromes with renal failure among older adults, suggesting regional disparities and treatment implications.
Key Points
To evaluate mortality trends due to myelodysplastic syndromes and renal failure among U.S. adults aged ≥65 from 1999 to 2023.
Utilized the CDC WONDER multiple cause of death database to identify relevant mortality cases.
Analyzed population aged ≥65 years with MDS and renal failure listed on death certificates.
Calculated age-adjusted mortality rates and annual percent change using JoinPoint regression analysis.
Identified 18,698 deaths attributed to MDS and renal failure from 1999 to 2023.
Noted a statistically significant rise in mortality rates from 1999 to 2012 with a non-significant trend afterwards.
Higher mortality rates observed in males and significant decline among Hispanic individuals.